{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-23-000121","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.580685+00:00","generated_at":"2026-06-10T21:37:02.011115+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio restructures $470M in debt; gets $200M new capital from founder","bullets":["Issued $200M convertible note to Nant Capital (founder affiliate) with 3-yr term, convertible at 50% premium to market price.","Exchanged $270M of existing debt for 209,291,936 shares of common stock, deleveraging balance sheet.","Extended $535M in debt maturities from Dec 2023 to Dec 2024.","Net proceeds of ~$199M to fund regulatory, pre-commercialization for Anktiva (N-803) in bladder cancer.","All transactions are related-party with Dr. Patrick Soon-Shiong, Executive Chairman and Global CSMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-23-000121","json":"https://secwatch.observer/filing/0001326110-23-000121.json","markdown":"https://secwatch.observer/filing/0001326110-23-000121.md","text":"https://secwatch.observer/filing/0001326110-23-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/ibrx-20230911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:37:02.011115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a23dfb99c10af05ad834dd29e576ee4eb505206","claim":"ImmunityBio, Inc. entered into Stock Purchase Agreement with Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC valued at approximately $270 million in aggregate principal amount (effective 2023-09-11).","evidence_excerpt":"Also on September 11, 2023, the Company, the Company’s wholly-owned subsidiary NantCell, Inc., Nant Capital, NantMobile, LLC (“NantMobile”) and NantCancerStemCell, LLC (“NCSC” and together with Nant Capital and NantMobile, the “Purchasers”), entered into a Stock Purchase Agreement (the “SPA”) pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the “Notes,” representing approximately $270 million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Nant Capital, LLC, NantMobile, LLC, NantCancerStemCell, LLC"},{"label":"Value","value":"approximately $270 million in aggregate principal amount"},{"label":"Effective","value":"2023-09-11"}],"fact_type":"material_agreement"},{"claim_id":"8b77166947b6c0d70313eae6021a4a991e3a684f","claim":"ImmunityBio, Inc. entered into $200.0 million Convertible Promissory Note with Nant Capital, LLC valued at $200.0 million (effective 2023-09-11).","evidence_excerpt":"On September 11, 2023, ImmunityBio, Inc. (the “Company”) executed a $200.0 million convertible promissory note with Nant Capital, LLC (“Nant Capital” or the “Investor”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Value","value":"$200.0 million"},{"label":"Effective","value":"2023-09-11"}],"fact_type":"material_agreement"},{"claim_id":"9fd610c22ebf4a478eb6a8120057cdbc41f29e9e","claim":"ImmunityBio, Inc. amended a notes offering with Nant Capital, LLC valued at approximately $535 million (effective 2023-09-11).","evidence_excerpt":"Also on September 11, 2023, the Company and Nant Capital entered into a series of letter agreements pursuant to which the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $535 million entered into between the Company and Nant Capital were each extended from December 31, 2023 to December 31, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Value","value":"approximately $535 million"},{"label":"Effective","value":"2023-09-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}